Exposure of Induced Pluripotent Stem Cell-Derived Vascular Endothelial and Smooth Muscle Cells in Coculture to Hemodynamics Induces Primary Vascular Cell-Like Phenotypes

Autor: Collado, MS, Cole, BK, Figler, RA, Lawson, M, Manka, D, Simmers, MB, Hoang, S, Serrano, F, Blackman, BR, Sinha, S, Wamhoff, BR

Human induced pluripotent stem cells (iPSCs) can be differentiated into vascular endothelial (iEC) and smooth muscle (iSMC) cells. However, because iECs and iSMCs are not derived from an intact blood vessel, they represent an immature phenotype. Hemo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c87c0feb4b5e5be0000fe7a1a03fae58

Development of a multicellular pancreatic tumor microenvironment system using patient-derived tumor cells.

Autor: Gioeli D; Departments of Microbiology, Immunology, and Cancer Biology, Virginia, USA. dgg3f@virginia.edu., Snow CJ, Simmers MB, Hoang SA, Figler RA, Allende JA, Roller DG, Parsons JT, Wulfkuhle JD, Petricoin EF, Bauer TW, Wamhoff BR

Publikováno v: Lab on a chip [Lab Chip] 2019 Mar 27; Vol. 19 (7), pp. 1193-1204.

Hemodynamics associated with atrial fibrillation directly alters thrombotic potential of endothelial cells.

Autor: Simmers MB; HemoShear Therapeutics, LLC, Charlottesville, VA, United States., Cole BK; HemoShear Therapeutics, LLC, Charlottesville, VA, United States., Ogletree ML; Merck & Co, Merck Research Labs, Rahway, NJ, United States. Electronic address: Martin.Ogletree@Vanderbilt.edu., Chen Z; Merck & Co, Merck Research Labs, Rahway, NJ, United States., Xu Y; Merck & Co, Merck Research Labs, Rahway, NJ, United States., Kong LJ; Merck & Co, Merck Research Labs, Rahway, NJ, United States., Mackman N; University of North Carolina, Chapel Hill, NC, United States., Blackman BR; HemoShear Therapeutics, LLC, Charlottesville, VA, United States., Wamhoff BR; HemoShear Therapeutics, LLC, Charlottesville, VA, United States. Electronic address: Wamhoff@HemoShear.com.

Publikováno v: Thrombosis research [Thromb Res] 2016 Jul; Vol. 143, pp. 34-9. Date of Electronic Publication: 2016 Apr 27.

An In Vitro Cynomolgus Vascular Surrogate System for Preclinical Drug Assessment and Human Translation.

Autor: Cole BK; From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)., Simmers MB; From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)., Feaver R; From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)., Qualls CW Jr; From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)., Collado MS; From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)., Berzin E; From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)., Figler RA; From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)., Pryor AW Jr; From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)., Lawson M; From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)., Mackey A; From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)., Manka D; From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)., Wamhoff BR; From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)., Turk JR; From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)., Blackman BR; From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.). Blackman@HemoShear.com.

Publikováno v: Arteriosclerosis, thrombosis, and vascular biology [Arterioscler Thromb Vasc Biol] 2015 Oct; Vol. 35 (10), pp. 2185-95. Date of Electronic Publication: 2015 Aug 20.

Atherosclerosis-prone hemodynamics differentially regulates endothelial and smooth muscle cell phenotypes and promotes pro-inflammatory priming.

Autor: Hastings NE; Department of Biomedical Engineering, University of Virginia, Charlottesville, VA 22908, USA., Simmers MB, McDonald OG, Wamhoff BR, Blackman BR

Publikováno v: American journal of physiology. Cell physiology [Am J Physiol Cell Physiol] 2007 Dec; Vol. 293 (6), pp. C1824-33. Date of Electronic Publication: 2007 Oct 03.